[{"data":1,"prerenderedAt":23},["ShallowReactive",2],{"$fbQm4PWc_340A56x2f7AVLgF1HNpAlLwYLRHpau45xJ0":3},{"card":4,"examId":6,"chapterTitle":20,"prev":21,"next":22},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":12,"explanation":13,"explanationDetail":14,"mistakeHint":14,"lectureRef":14,"storyRef":14,"chapterSlug":15,"sectionCode":16,"sectionTitle":17,"clusterSlug":18,"term":14,"sequenceOrder":14,"regionWeight":14,"revisionMark":14,"isActive":19},"ch5-041","touhan","生物由来製品の定期的安全性評価報告制度が導入されたのは2003年7月からである。",0,[10,11],"正しい","誤り","ox","2003年7月から、血液製剤等の生物由来製品の製造販売企業に対し、感染症に関する最新の論文・知見に基づく安全性評価を定期的に国へ報告する制度が導入されました。",null,"chapter-5","5-II-1","副作用情報等の収集","fukusayou-shuushuu",true,"第5章 医薬品の適正使用・安全対策","ch5-040","ch5-042",1784619074267]